Facebook

Spotlight on…

The 3P Project: A new approach to developing better treatments for TB

The 3P Project is a new approach to developing affordable, effective new drug regimens to treat tuberculosis, an ancient disease that still kills 1.5 million people a year.  New treatments are urgently needed, particularly for drug-resistant forms of the disease; today's drug regimens are lengthy, toxic, expensive and only about 50% effective.

The 3P Project uses an open collaborative approach to conduct drug research and development (R&D), and uses novel approaches to finance and coordinate the process.

What are the 3 "P"s?  Watch this video to find out!

Ensuring a healthy pipeline: rethinking TB drug research and development

Research and development of TB drugs suffers from significant weaknesses throughout all stages of the research process, hampering the development of new regimens. The way TB drug research is done today is not adequately responding to the needs of patients and TB programmes.
With chronic underfunding and major pharmaceutical companies withdrawing or reducing their investment in TB R&D, novel approaches must be considered to re-energise the pipeline, bring new funders to the arena, prioritise regimen development early in the drug development process, and ensure access and affordability for products.
 
Push, pull and pool: accelerating innovation and access for new treatment regimens for TB with MSF’s ‘3P Proposal’
 

Push, pull and pool: accelerating innovation and access for new treatment regimens for TB with MSF’s ‘3P Proposal’

MSF, in collaboration with other partners, has developed a proposal for an alternative way to conduct research and development for TB regimens that addresses some of the shortcomings of the current drug development landscape. The aim is to ensure a steady supply of new  TB drugs for regimen development. The ‘3P Project’ aims to create a new open collaborative framework for regimen development by implementing push, pull and pool incentive mechanisms to facilitate the necessary and appropriate R&D for TB medicines:
  • - Push funding to finance R&D activities upfront (i.e. through grants); 
  • - Pull funding to incentivise R&D activities through the promise of financial rewards on the achievement of certain R&D objectives (i.e. through milestone prizes);
  • - Pooling of data and intellectual property to ensure  open collaborative research and to ensure fair licensing for competitive production of the final products.
These well-targeted incentives aim to bring new researchers and developers to the problem, re-engage traditional investors in TB drug development, ensure a healthy drug development pipeline, and ensure that several drug candidates are developed in parallel as combination regimens. More information on the '3P Project'
 

5 articles related to "The 3P Project: A new approach to developing better treatments for TB"
↑ To top